The Omicron variant sub-type BA.2, informally dubbed "stealth Omicron." has unfold to at the least 74 international locations worldwide, knowledge reveals.

BA.2 has accounted for an growing proportion of COVID instances in lots of international locations in comparison with the BA.1 Omicron sub-type, which has been largely dominant thus far.

Information has recommended for weeks that BA.2 seems to have a major progress benefit over BA.1. The extent of every other modifications, nevertheless, stay much less clear.

Outbreak.information, which collects variant knowledge from the virus genome database GISAID, reveals that as of Wednesday BA.2 had been present in 74 international locations and 47 U.S. states.

Regardless of BA.2's noticed progress benefit, the variant seems to have been reported as dominant in solely a few international locations—Denmark and South Africa—although it is attainable it might be dominant in others.

On February 3, Denmark's Statens Serum Institut (SSI) reported that BA.2 accounted for 69 p.c of latest COVID instances and was anticipated to account for as much as 100% of latest instances by the center of this month.

Extra just lately, on February 10, John Nkengasong, director of the Africa Centres for Illness Management and Prevention (CDC), stated in a press briefing that BA.2 had turn out to be "the predominant variant" in South Africa.

Nkengasong added that the variant had been present in different African nations like Mozambique, Senegal, Botswana, Mauritius, Kenya and Malawi, in keeping with Reuters.

In some international locations the variant is spreading noticeably however has but to make up something like the vast majority of instances. The U.Ok. has been reporting BA.2 instances for a number of weeks, however in keeping with a technical briefing revealed by the nation's Well being Safety Company (HSA) on February eleventh, BA.2 accounted for 4.1 p.c of instances whereas BA.1 accounted for 95.4 p.c of them.

It must be famous that these figures have been primarily based on sequencing knowledge as much as January thirty first, so they could have modified considerably since then.

In the meantime within the U.S., BA.2 was estimated to account for 3.9 p.c of latest sequenced COVID instances between the dates of February 6 and February 12, with different Omicron varieties accounting for primarily the entire remaining 96.1 p.c of instances in keeping with Facilities for Illness Management and Prevention (CDC) knowledge.

Dr. Scott Gottlieb, a U.S. doctor and former commissioner of the Meals and Drug Administration (FDA), has expressed optimism that BA.2 is not going to make a major distinction to the U.S.' latest lower in COVID instances. He tweeted final week: "Whereas it might turn out to be a dominant pressure in time, it seems more and more unlikely that it'll trigger a major change within the downward trajectory of the present epidemic wave."

As talked about, many elements of BA.2, equivalent to vaccine resistance and reinfection functionality, are nonetheless unclear. Experiences from the U.Ok.'s HSA have famous that it seems as if individuals with booster pictures are capable of battle off symptomatic illness from BA.2 and BA.1 equally nicely. The well being physique additionally famous on February eleventh that there have been no confirmed instances of somebody in England being contaminated with BA.2 after already having had BA.1.

Nevertheless, a pre-print and non-peer-reviewed examine launched by Japanese researchers on Tuesday this week recommended BA.2 could also be extra pathogenic, or able to inflicting illness, than BA.1 and that "vaccine-induced humoral immunity fails to perform in opposition to BA.2 like BA.1". The findings have been primarily based on animal research and "neutralization experiments."

COVID test site
A photograph reveals a well being employee dealing with what look like take a look at tubes at a COVID testing website in Nootdorp, Netherlands, on January twenty fifth, 2022. BA.2 has turn out to be dominant in a few international locations.Patrick van Katwijk/Getty